
# Complications in ACS with Primary PTCA

DR. A.M.THIRUGNANAM
MD, MSICP, PHD, FSCAI.
SENIOR INTERVENTIONAL CARDIOLOGIST,

# Progression of Atherosclerosis



### PTCA technique



# **ACS- Its Complications**

MECHANICAL- VSR, PMR, PSEUDO ANEURYSM ELECTRICAL-ARRHYTHMIAS, AVB HEMODYANMICS- CARDIOGENIC SHOCK FOCAL MYOCARDIAL- MYOCARDIAL STUNNING, HIBERNATION, EDEMA

### **Mechanical Complications**

- VSR- occurs between 3-7 days after MI
- PMR- occurs between 2-7 days
- Pseudo aneurysm- occurs after one week.
- Treatment: inotropes, IABP, TPI, vasodilators
- Prognosis: worst with PMR, VSR, and aneurysm.

### **Electrical Complications**

- Non fatal Arrhythmias: Reperfusion arrhythmias, occational VPC, junctional rhythm, 1<sup>st</sup> degree AVB, 2<sup>nd</sup> degree Mobitz type-I.
- Treatment: Observe and treat.
- Fatal Arrhythmias: VF, VT, T wave alternans,
- Treatment: DC shock, Anti Arrhythmic drugs, like amiodarone, lidocaine, adenosine, etc

### Hemodynamic Complications

- Cardiogenic Shock: Tachycardia, urine out <30 ml/hr,</li>
- Persistent hypotension for >30 min, Less than SBP-80mmhg.
- Bilateral lungs crackles and rales
- Pulmonary edema
- Saturation <85%</p>
- Severe LV dysfunction

### Myocardial dysfunction

- Myocardial stunning, hibernation, edema, increased level of hCRP, TNF-alpha, IL-1, IL-6, PAI-1, cardiac troponin level, CD-40 ligand, and BNP
- Effects of myocardial dysfunction: slow flow, no flow and acute stent thrombosis.
- Treatments: ACEI, Statins, Antiplatelets, anticoagulants, inotropes, aldosterone receptor blocker, IABP, Impella device, and GP2b3a Inhibitors.

### When to intervene in ACS?

- In STEMI- door to ECG in 15 min.
- Door to thrombolytic in 30 min.
- Door to balloon in 60 min.
- Primary PTCA in 90 min
- On going chest pain,
- Persistent STE
- Viable myocardium in the culprit vessel supplying area.

#### When not to intervene?

- Cardiogenic shock with WP more than 24 hrs
- ECG- T wave variant
- Fresh RBBB and LBBB with shock
- Increased creatinine with shock
- Hba1c more than 9
- Arrhythmias and shock
- Where the effective, skilled and experienced team is not available.


### SCD- male with STEMI-WP 3 days

	0.5 / 1.5 / 2.0 1.0																ВЕ			Dept:					
Rx: Dx:		Mr.			V.	0.	Simon		48	- (n	male									Roo	m:				
Rate PR ORSD OT OTe	1.5.0																			Reque	este	d by:			
e AX P QRS T	1S 52 26 130																								
						1	VR					CI.							0.4						
										-														~_	
14			4042		1,					Y				Ì					ÿ				- 17		
													1 1												
							VI.					-(2							€5			4	1		
										1															Elil
			Α									- /			A										
NH					N-				,	7		- 1	4/		1.	14/		1	1			WY	TV		
															1	. 1									
1:1						i a	VY					0.3							- 66						
																						1			
1	-				1				1	1															
-		114.	-, 1-	4444					2			-	Mr	1		11/				4	4		111/		
19					¥	I V																			
																									411
					ALL-						4.4						1-1		لاسلا	~		JUL	##	4	
٧																									
								(1) H		C h											ii. V	1112			

### Case -1, 63 yr/male STEMI, AWMI

- History: DM for 20 yrs, HTN-20 yrs, not on proper treatment.
- ECG- ST elevation in V1-V5 more than 10mm
- HR-105/min, O2-95%, RR-24/min, lungs- clear, SBP-100mmhg, RBG-75 mg/dl, Cr-3.5/mg/dl,
- WP more than 8 hrs.
- On going chest pain is present.


### LAD- 100% occlusion




# LAD wiring only with fluro



# LAD wiring with predilatation




# Deployment of Stent



### Post Dilatation inside stent



## Final result of LAD stenting




### Case-2, 32/male, No DM, No HTN


- Came on 3<sup>rd</sup> day after chest pain.
- BP-110/80mmhg, HR-110/min,
- Lungs- clear, O2-96% at room air,
- ECG-ST elevation in V1-V5.
- Echo-45%, with moderate LV dysfunction.
- C/O- weakness, sweating, persistent chest discomfort, nausea and palpitation.

### ECG- ST elevation in V1-V5


1/9/2010 7:04:48 PM Unknown




### 2<sup>nd</sup> ECG before PTCA




### LAD total occlusion




# LAD wiring




### Predilatation with balloon




### No flow after Predilatation




### Using Thrombus Extraction Catheter




### TIMI-III flow after TEC




# Deployment of stent




### Final results



### 3rd ECG after PTCA




### Case-3 Evolution of ECG changes in MI ECG1




### ECG-2







### ECG-3, after STK



### ECG-4, after PTCA




### ECG-5, PTCA 2<sup>nd</sup> day




# ECG-6,





# Impella Device in High Risk PTCA



### IABP device in Current scenario

fesildeff@gmail.com

### Shall we believe still the thrombolytic?

- In ACS with STEMI and NSTEMI, Primary PTCA or rescue PTCA is the only option.
- Thrombolytic gives only 40% perfusion in TIMI-II
- Most of the MI related complications occurs only in thrombolytic regime and delay in treatment.
- Non diabetic, non hypertensive and non smoker young individual still have some benefits of thrombolytic.

### What are the benefits of Primary PTCA?

- Decreases morbidity and mortality
- Reduces and prevents complications
- Prevents future CHF
- Reduces hospitalization
- Reduces treatment costs

### Home taking messages

- Early recognition of STEMI
- Early mobilization
- PTCA with in 60 min Prevent mortality
- No substitute treatment is available for ACS except primary PTCA.
- Advanced cardiac devices in high risk PTCA will reduces mortality and morbidity.
- If cath lab is not available, treat only with effective measures.